Abstract
Poly(ADP-ribose) glycohydrolase (Parg) is the main enzyme for degradation of poly(ADP-ribose) by splitting ribose-ribose bonds. Parg-deficient (Parg+/- and Parg-/-) mouse ES cell lines have been established by disrupting both alleles of Parg exon 1 through gene-targeting. A transcript encoding a full length isoform of Parg was eliminated and only low amounts of Parg isoforms were detected in Parg-/- embryonic stem (ES) cells. Poly(ADP-ribose) degradation activity was decreased to one-tenth of that in Parg+/+ ES cells. Parg-/- ES cells exhibited the same growth rate as Parg+/+ ES cells in culture. Sensitivity of Parg-/- ES cells to various DNA damaging agents, including an alkylating agent dimethyl sulfate, cisplatin, gemcitabine, 5-fluorouracil, camptothecin, and γ-irradiation was examined by clonogenic survival assay. Parg-/- ES cells showed enhanced lethality after treatment with dimethyl sulfate, cisplatin and γ-irradiation compared with wildtype (Parg+/+) ES cells (p < 0.05, respectively). In contrast, a sensitization effect by Parg-deficiency was not observed with gemcitabine and camptothecin. These results suggest the possibility that functional inhibition of Parg leads to sensitization of tumor cells to some chemo- and radiation therapies.
Keywords: Poly(ADP-ribose) glycohydrolase, Knockout, ES cell, DNA damaging agent, Alkylating agent, γ-irradiation, cisplatin, 5-fluorouracil
Current Cancer Drug Targets
Title: Poly(ADP-ribose) Glycohydrolase Deficiency Sensitizes Mouse ES Cells to DNA Damaging Agents
Volume: 9 Issue: 8
Author(s): H. Fujihara, H. Ogino, D. Maeda, H. Shirai, T. Nozaki, N. Kamada, K. Jishage, S. Tanuma, T. Takato, T. Ochiya, T. Sugimura and M. Masutani
Affiliation:
Keywords: Poly(ADP-ribose) glycohydrolase, Knockout, ES cell, DNA damaging agent, Alkylating agent, γ-irradiation, cisplatin, 5-fluorouracil
Abstract: Poly(ADP-ribose) glycohydrolase (Parg) is the main enzyme for degradation of poly(ADP-ribose) by splitting ribose-ribose bonds. Parg-deficient (Parg+/- and Parg-/-) mouse ES cell lines have been established by disrupting both alleles of Parg exon 1 through gene-targeting. A transcript encoding a full length isoform of Parg was eliminated and only low amounts of Parg isoforms were detected in Parg-/- embryonic stem (ES) cells. Poly(ADP-ribose) degradation activity was decreased to one-tenth of that in Parg+/+ ES cells. Parg-/- ES cells exhibited the same growth rate as Parg+/+ ES cells in culture. Sensitivity of Parg-/- ES cells to various DNA damaging agents, including an alkylating agent dimethyl sulfate, cisplatin, gemcitabine, 5-fluorouracil, camptothecin, and γ-irradiation was examined by clonogenic survival assay. Parg-/- ES cells showed enhanced lethality after treatment with dimethyl sulfate, cisplatin and γ-irradiation compared with wildtype (Parg+/+) ES cells (p < 0.05, respectively). In contrast, a sensitization effect by Parg-deficiency was not observed with gemcitabine and camptothecin. These results suggest the possibility that functional inhibition of Parg leads to sensitization of tumor cells to some chemo- and radiation therapies.
Export Options
About this article
Cite this article as:
Fujihara H., Ogino H., Maeda D., Shirai H., Nozaki T., Kamada N., Jishage K., Tanuma S., Takato T., Ochiya T., Sugimura T. and Masutani M., Poly(ADP-ribose) Glycohydrolase Deficiency Sensitizes Mouse ES Cells to DNA Damaging Agents, Current Cancer Drug Targets 2009; 9 (8) . https://dx.doi.org/10.2174/156800909790192419
DOI https://dx.doi.org/10.2174/156800909790192419 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology New Technologies in Male Contraception
Current Women`s Health Reviews Heparanase Inhibitors Facilitate the Assembly of the Basement Membrane in Artificial Skin
Current Tissue Engineering (Discontinued) HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design CD147 Promotes Melanoma Progression Through Hypoxia-Induced MMP2 Activation
Current Molecular Medicine Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Hsp70 Molecular Chaperones: Emerging Roles in Human Disease and Identification of Small Molecule Modulators
Current Topics in Medicinal Chemistry Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry The Protective Effects and Mechanism of Resveratrol-loaded Nanoparticles on HK-2 Cells Suffering from Hypoxia-reoxygenayion
Current Signal Transduction Therapy Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy